EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Intermittent Claudication - Pipeline Review, H1 2017

  • ID: 4091147
  • Report
  • February 2017
  • 48 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • ID Pharma Co Ltd
  • Kowa Company Ltd
  • Nuo Therapeutics Inc
  • MORE
Intermittent Claudication - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Intermittent Claudication - Pipeline Review, H1 2017, provides an overview of the Intermittent Claudication (Cardiovascular) pipeline landscape.

Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs and sores or wounds on the lower limb that heal slowly, poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age and family history.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Intermittent Claudication - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Intermittent Claudication (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Intermittent Claudication (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Discovery stages are 1, 4 and 1 respectively.

Intermittent Claudication (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Intermittent Claudication (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Intermittent Claudication (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Intermittent Claudication (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Intermittent Claudication (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Intermittent Claudication (Cardiovascular).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Intermittent Claudication (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Intermittent Claudication (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ID Pharma Co Ltd
  • Kowa Company Ltd
  • Nuo Therapeutics Inc
  • MORE
Introduction

Intermittent Claudication - Overview

Intermittent Claudication - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Intermittent Claudication - Companies Involved in Therapeutics Development

Genovate Biotechnology Co LTD

ID Pharma Co Ltd

Kowa Company Ltd

Nuo Therapeutics Inc

Pluristem Therapeutics Inc

Intermittent Claudication - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Intermittent Claudication - Drug Profiles

ALD-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilostazol CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DVC-10101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-134 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-2003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-PAD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Intermittent Claudication - Dormant Projects

Intermittent Claudication - Discontinued Products

Intermittent Claudication - Product Development Milestones

Featured News & Press Releases

Jan 12, 2017: Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication

May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial

Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications

Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea

Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel

Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study

Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells

Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study

Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany

Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells

Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research

Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study

Apr 17, 2012: Pluristem Receives FDA Clearance For Phase II Clinical Trial In Intermittent Claudication

Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134

Dec 02, 2011: Kowa Releases Japan Phase IIb Clinical Trials Data Of Anti-Platelet Agent, K-134

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Intermittent Claudication, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Intermittent Claudication - Pipeline by Genovate Biotechnology Co LTD, H1

Intermittent Claudication - Pipeline by ID Pharma Co Ltd, H1

Intermittent Claudication - Pipeline by Kowa Company Ltd, H1

Intermittent Claudication - Pipeline by Nuo Therapeutics Inc, H1

Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Intermittent Claudication - Dormant Projects, H1

Intermittent Claudication - Discontinued Products, H1

List of Figures:

Number of Products under Development for Intermittent Claudication, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Genovate Biotechnology Co LTD
  • ID Pharma Co Ltd
  • Kowa Company Ltd
  • Nuo Therapeutics Inc
  • Pluristem Therapeutics Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll